FLT3-ITD mutations are associated with lower overall survival (OS) rate, poor treatment response, and shorter disease-free survival (DFS), which makes FLT3 an appealing treatment target in AML [9, 10]. This evidence concerns the gene FLT3 and acute myeloid leukemia.